Mentoring and Research in Patient-Oriented Cardiovascular Pharmacoepidemiology

摘要 此应用程序将为首席调查员Pamela Lutsey博士提供受保护的时间和其他 支持1)加快指导初级临床研究人员和研究生的成功记录 从事心血管疾病(CVD)患者导向研究(POR)，2)获得以下方面的额外培训 药物流行病学、组学和指导最佳实践和3)促进她正在进行的CVD 药物流行病学研究计划。药物在预防和治疗中发挥着至关重要的作用 心脑血管疾病和其他病症。为了提高药物干预对心血管疾病结局的有效性， 我们需要初级临床研究人员进行POR，他们在这些领域有严格的培训和指导 药物流行病学、心血管疾病临床流行病学、翻译研究方法和使用 复杂的数据源。作为这些领域的专家，候选人卢西博士建议应用K24基金 为明尼苏达大学致力于研究的POR学者提供指导 职业生涯将通过建立关于如何减少心血管疾病负担的严格证据来减轻人群的负担 优化药物使用，以预防高危人群中的心血管疾病，降低 心血管疾病患者的复发。目标1涉及进行药物流行病学POR比较 预防高危人群心血管疾病和改善心血管疾病预后的有效性研究 幸存者。最先进的药物流行病学技术将应用于大型管理数据 来源，特别是MarketScan和Medicare 20%的样本。目标2将从深度利用丰富的数据 表型队列以了解影响药物疗效的行为特征， 并收集了对药物治疗作用的生理机制的了解。这些 分析将使用来自社区动脉粥样硬化风险(ARIC)研究和多种族研究的数据 动脉粥样硬化(MESA)。拟议目标的调查结果将促进对特定目标的作用的理解 心血管疾病风险的药物治疗策略，并有可能直接影响临床实践， 加强或导致重新考虑现有的临床指南。这份提案的结构是允许 受训者可以根据自己的临床经验和兴趣灵活地提出自己的假设。 在K24的支持下，Lutsey博士计划扩大她POR研究活动的广度，招募新的 初级临床学者进入POR，并为他们取得重大科学进步和推出自己的产品做好准备 独立研究职业。

SUMMARY This application will provide the Principal Investigator, Dr. Pamela Lutsey, with protected time and other support to 1) accelerate a successful record of mentoring junior clinical investigators and graduate students engaged in cardiovascular disease (CVD) patient-oriented research (POR), 2) obtain additional training in pharmacoepidemiology, -omics and mentoring best practices and 3) advance her ongoing CVD pharmacoepidemiology research program. Pharmaceuticals play a crucial role in the prevention and treatment of CVD and other conditions. To improve the effectiveness of pharmacologic interventions on CVD outcomes, we need junior clinical investigators conducting POR who have rigorous training and mentorship in the areas of pharmacoepidemiology, clinical epidemiology of CVD, translational research methods and the use of complex data sources. An expert in these areas, the candidate, Dr. Lutsey, proposes to apply K24 funds toward the mentorship of POR scholars at the University of Minnesota who are committed to a research career that will reduce the burden of CVD in the population through building rigorous evidence regarding how to optimize use of pharmaceuticals in order to prevent CVD in at-risk populations and reduce risk of recurrence among individuals with CVD. Aim 1 involves conducting pharmacoepidemiology POR comparative effectiveness research to prevent CVD in at-risk populations and improve the outcomes among CVD survivors. State-of-the-art pharmacoepidemiologic techniques will be applied to large administrative data sources, specifically MarketScan and the Medicare 20% sample. Aim 2 will harness rich data from deeply phenotyped cohorts to understand behavioral characteristics that influence the effectiveness of medications, and glean added understanding of the physiologic mechanisms through which pharmacotherapies act. These analyses will use data from the Atherosclerosis Risk in Communities (ARIC) study and the Multi-Ethnic Study of Atherosclerosis (MESA). Findings from the proposed Aims will advance understanding of the role of specific pharmacologic treatment strategies on CVD risk, and have potential to directly impact clinical practice, reinforcing or leading to reconsideration of existing clinical guidelines. This proposal is structured to allow trainees the flexibility to pursue their own hypotheses, motivated by their clinical experiences and interests. With support from this K24, Dr. Lutsey plans to expand the breadth of her POR research activities, recruit new junior clinical scholars into POR, and prepare them to make major scientific advances and launch their own independent research careers.